Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 12 | 2024 | 515 | 3.310 |
Why?
|
| Acute Coronary Syndrome | 7 | 2024 | 210 | 3.050 |
Why?
|
| Chest Pain | 12 | 2024 | 232 | 1.570 |
Why?
|
| Troponin T | 7 | 2024 | 98 | 1.420 |
Why?
|
| Cardiology | 5 | 2024 | 110 | 1.350 |
Why?
|
| Troponin | 8 | 2024 | 114 | 1.260 |
Why?
|
| Emergency Medical Services | 5 | 2023 | 189 | 1.190 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 103 | 0.870 |
Why?
|
| Adult | 30 | 2024 | 10015 | 0.810 |
Why?
|
| Mortality | 2 | 2020 | 127 | 0.760 |
Why?
|
| Prospective Studies | 15 | 2024 | 2461 | 0.740 |
Why?
|
| Nursing Staff | 1 | 2022 | 7 | 0.720 |
Why?
|
| Emergency Service, Hospital | 11 | 2024 | 502 | 0.720 |
Why?
|
| Humans | 54 | 2024 | 34474 | 0.710 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 30 | 0.700 |
Why?
|
| Hospitalization | 3 | 2023 | 500 | 0.700 |
Why?
|
| Middle Aged | 34 | 2024 | 12703 | 0.690 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 229 | 0.660 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 934 | 0.660 |
Why?
|
| Hypercholesterolemia | 3 | 2023 | 74 | 0.570 |
Why?
|
| Ethnic Groups | 1 | 2020 | 483 | 0.550 |
Why?
|
| Female | 34 | 2024 | 21490 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 5 | 2022 | 140 | 0.510 |
Why?
|
| Deglutition Disorders | 2 | 2014 | 53 | 0.500 |
Why?
|
| Male | 26 | 2024 | 20697 | 0.470 |
Why?
|
| Mass Screening | 3 | 2023 | 268 | 0.470 |
Why?
|
| Aged | 23 | 2024 | 10998 | 0.440 |
Why?
|
| Models, Statistical | 1 | 2014 | 193 | 0.390 |
Why?
|
| Neoplasms | 4 | 2024 | 791 | 0.370 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2017 | 50 | 0.350 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3618 | 0.340 |
Why?
|
| Death | 4 | 2024 | 53 | 0.330 |
Why?
|
| Algorithms | 5 | 2024 | 560 | 0.330 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 441 | 0.310 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 12 | 0.280 |
Why?
|
| North Carolina | 7 | 2023 | 1612 | 0.280 |
Why?
|
| Cohort Studies | 10 | 2024 | 1910 | 0.270 |
Why?
|
| Atherosclerosis | 2 | 2023 | 837 | 0.250 |
Why?
|
| Caregivers | 3 | 2024 | 116 | 0.250 |
Why?
|
| Quality of Life | 6 | 2022 | 1032 | 0.250 |
Why?
|
| Postoperative Complications | 3 | 2017 | 849 | 0.250 |
Why?
|
| Decision Making | 2 | 2022 | 203 | 0.240 |
Why?
|
| Tamoxifen | 2 | 2017 | 66 | 0.240 |
Why?
|
| Young Adult | 11 | 2024 | 2825 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 489 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2020 | 480 | 0.230 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 1209 | 0.230 |
Why?
|
| Logistic Models | 4 | 2020 | 808 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3812 | 0.210 |
Why?
|
| United States | 5 | 2024 | 4267 | 0.210 |
Why?
|
| Consensus | 1 | 2024 | 91 | 0.200 |
Why?
|
| Government Programs | 1 | 2023 | 11 | 0.200 |
Why?
|
| Rural Population | 2 | 2023 | 297 | 0.190 |
Why?
|
| Colonoscopy | 1 | 2023 | 45 | 0.190 |
Why?
|
| Adolescent | 9 | 2023 | 3799 | 0.190 |
Why?
|
| Primary Health Care | 2 | 2022 | 240 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 61 | 0.190 |
Why?
|
| Risk Factors | 8 | 2024 | 4136 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2024 | 1506 | 0.190 |
Why?
|
| Tablets | 1 | 2022 | 11 | 0.180 |
Why?
|
| Olfaction Disorders | 1 | 2021 | 8 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 34 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 168 | 0.170 |
Why?
|
| Cross Infection | 1 | 2021 | 62 | 0.170 |
Why?
|
| Bacteremia | 1 | 2021 | 69 | 0.170 |
Why?
|
| Coronary Disease | 1 | 2022 | 239 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 83 | 0.170 |
Why?
|
| Time Factors | 6 | 2024 | 2352 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2023 | 216 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 15 | 0.160 |
Why?
|
| Teratoma | 1 | 2020 | 9 | 0.160 |
Why?
|
| Ambulances | 1 | 2020 | 12 | 0.160 |
Why?
|
| Transportation of Patients | 1 | 2020 | 25 | 0.160 |
Why?
|
| Naloxone | 1 | 2020 | 33 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 47 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2020 | 39 | 0.150 |
Why?
|
| Medical Oncology | 2 | 2018 | 93 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 819 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 136 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 183 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2020 | 120 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1607 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 707 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 24 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 184 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 245 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 265 | 0.130 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2017 | 2 | 0.130 |
Why?
|
| Estrogen Antagonists | 1 | 2017 | 20 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 8 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 24 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 25 | 0.120 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1176 | 0.120 |
Why?
|
| Esophagectomy | 1 | 2015 | 18 | 0.120 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 10 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 42 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 46 | 0.110 |
Why?
|
| Gastrectomy | 1 | 2015 | 70 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 273 | 0.110 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 7 | 0.110 |
Why?
|
| Alleles | 1 | 2015 | 257 | 0.110 |
Why?
|
| Hispanic Americans | 1 | 2020 | 948 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 228 | 0.110 |
Why?
|
| Anxiety | 1 | 2016 | 206 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 64 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 33 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 113 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 32 | 0.100 |
Why?
|
| Lymphoma | 1 | 2014 | 40 | 0.100 |
Why?
|
| Health Services | 1 | 2014 | 42 | 0.100 |
Why?
|
| African Americans | 1 | 2020 | 1435 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2013 | 19 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 14 | 0.100 |
Why?
|
| Esophageal Stenosis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Dilatation | 1 | 2013 | 9 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 23 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 4150 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2013 | 19 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 250 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2366 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 93 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 44 | 0.100 |
Why?
|
| Survivors | 1 | 2014 | 177 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2013 | 161 | 0.090 |
Why?
|
| Parents | 1 | 2013 | 159 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 133 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 177 | 0.090 |
Why?
|
| Deglutition | 1 | 2011 | 30 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 70 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 803 | 0.080 |
Why?
|
| Acute Disease | 2 | 2021 | 276 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 703 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 612 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 1244 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 803 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2016 | 104 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 801 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 1603 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 168 | 0.050 |
Why?
|
| Workplace | 1 | 2023 | 52 | 0.050 |
Why?
|
| Phenotype | 2 | 2015 | 656 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2023 | 168 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2022 | 25 | 0.050 |
Why?
|
| Health Education | 1 | 2023 | 170 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 273 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 191 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2021 | 3 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2021 | 5 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 267 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 185 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 29 | 0.040 |
Why?
|
| Taste | 1 | 2021 | 18 | 0.040 |
Why?
|
| Focus Groups | 1 | 2022 | 125 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 446 | 0.040 |
Why?
|
| Smell | 1 | 2021 | 47 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 264 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2613 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1261 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 323 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 199 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 46 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2020 | 14 | 0.040 |
Why?
|
| Bleomycin | 1 | 2020 | 13 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 20 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 197 | 0.040 |
Why?
|
| Life Support Care | 1 | 2020 | 14 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 42 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 583 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 63 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 88 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 176 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 98 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 231 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 540 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 217 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2020 | 730 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 1386 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Women's Health Services | 1 | 2016 | 12 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 128 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 155 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 350 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1354 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 657 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 452 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 149 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 341 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 399 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 328 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 43 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 49 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 743 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 411 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 58 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 75 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 180 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 925 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 464 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 141 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 207 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 458 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 2011 | 17 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1288 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 88 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 214 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 251 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 589 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 922 | 0.020 |
Why?
|